Literature DB >> 24658886

Prediction of left atrial thrombi in patients with atrial tachyarrhythmias during warfarin administration: retrospective study in Hyogo College of Medicine.

Hideyuki Kishima, Takanao Mine, Takeshi Kodani, Tohru Masuyama.   

Abstract

Some patients experience a left atrial thrombus (LAT) in spite of taking warfarin. We aimed to clarify the characteristics of patients with LAT during warfarin administration and investigated whether the CHADS2 or CHA2DS2-VASc scores are useful predictors of LAT. We studied 230 patients (169 males, age 65 ± 10 years) who underwent transesophageal echocardiography (TEE) prior to cardioversion or catheter ablation of atrial tachyarrhythmias between 2008 and 2012. All patients were taking oral warfarin. LAT was detected in 19 patients (8.3%) using TEE. LAT was significantly associated with the presence of hypertension (P = 0.0035), prior congestive heart failure (P < 0.0001), structural heart disease (P = 0.0012), persistent arrhythmias (P < 0.0001), the absence of SR during TEE (P = 0.0070), left ventricular ejection fraction (P < 0.0001), left atrial diameter (P = 0.0015), left ventricular dimension during end diastole (P = 0.0215), left ventricular hypertrophy (LVH; P < 0.0001), and the E/e' ratio (P = 0.0074). A multivariate analysis showed that LVH (P = 0.0065, OR 5.591, 95% CI 1.618–19.316) and persistent arrhythmia (P = 0.0364, OR 12.121, 95% CI 1.171–125.451) were independently associated with LAT. Moreover, the mean CHADS2 (2.3 ± 0.9 vs. 1.4 ± 1.2) and CHA2DS2-VASc scores (3.8 ± 1.2 vs. 2.8 ± 1.7) were higher in the patients with than without LAT. However, a multivariate analysis showed that the CHADS2/CHA2DS2-VASc scores did not associate with LAT. LVH and persistent arrhythmia may be useful for predicting LAT in patients with atrial tachyarrhythmias.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24658886     DOI: 10.1007/s00380-014-0496-5

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  25 in total

1.  Transesophageal echocardiography for thrombus screening prior to left atrial catheter ablation.

Authors:  Eiji Yamashita; Hiroto Takamatsu; Hiroshi Tada; Hiroyuki Toide; Hiroki Okaniwa; Naoki Takemura; Takehito Sasaki; Yuko Miki; Etsuko Fuke; Tatsuya Hayashi; Tamotsu Sakamoto; Koki Nakamura; Rie Fukazawa; Chizuru Sato; Koji Goto; Kenichi Kaseno; Koji Kumagai; Shigeto Naito; Hiroshi Hoshizaki; Shigeru Oshima
Journal:  Circ J       Date:  2010-04-20       Impact factor: 2.993

2.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

Review 3.  Tachycardia-induced cardiomyopathy: a review of literature.

Authors:  Atul Khasnis; Krit Jongnarangsin; George Abela; Srikar Veerareddy; Vivek Reddy; Ranjan Thakur
Journal:  Pacing Clin Electrophysiol       Date:  2005-07       Impact factor: 1.976

Review 4.  HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Josep Brugada; Douglas L Packer; Riccardo Cappato; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; David E Haines; Michel Haissaguerre; Yoshito Iesaka; Warren Jackman; Pierre Jais; Hans Kottkamp; Karl Heinz Kuck; Bruce D Lindsay; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Andrea Natale; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Jeremy N Ruskin; Richard J Shemin
Journal:  Heart Rhythm       Date:  2007-04-30       Impact factor: 6.343

5.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

6.  A free-floating left atrial thrombus develops intermittent entrapment in the mid-ventricle during diastole.

Authors:  Mikiko Fujiwara; Hiroyuki Watanabe; Yasunori Oguma; Genbu Yamaura; Kazuyuki Ishibashi; Hiroshi Yamamoto; Kiyoshi Nobori; Kenji Iino; Fumio Yamamoto; Hiroshi Ito
Journal:  Heart Vessels       Date:  2011-11-02       Impact factor: 2.037

7.  Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. - Subanalysis of the J-RHYTHM Registry-.

Authors: 
Journal:  Circ J       Date:  2011-07-27       Impact factor: 2.993

8.  Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation.

Authors:  Daniel Scherr; Darshan Dalal; Karuna Chilukuri; Jun Dong; David Spragg; Charles A Henrikson; Saman Nazarian; Alan Cheng; Ronald D Berger; Theodore P Abraham; Hugh Calkins; Joseph E Marine
Journal:  J Cardiovasc Electrophysiol       Date:  2008-10-27

9.  Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis.

Authors:  DaLi Feng; Imran S Syed; Matthew Martinez; Jae K Oh; Allan S Jaffe; Martha Grogan; William D Edwards; Morie A Gertz; Kyle W Klarich
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

10.  Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study.

Authors:  W J Manning; R M Weintraub; C A Waksmonski; J M Haering; P S Rooney; A D Maslow; R G Johnson; P S Douglas
Journal:  Ann Intern Med       Date:  1995-12-01       Impact factor: 25.391

View more
  8 in total

1.  Clinical background including anticoagulant therapy in patients with atrial fibrillation in a community-based survey: the Saitama AF Registry.

Authors:  Yasushi Wakabayashi; Yoshitaka Sugawara; Kanna Fujita; Takekuni Hayashi; Nahoko Ikeda; Tomio Umemoto; Hiroshi Wada; Kenichi Sakakura; Hiroshi Funayama; Takeshi Mitsuhashi; Hideo Fujita; Shin-Ichi Momomura
Journal:  Heart Vessels       Date:  2017-06-20       Impact factor: 2.037

2.  Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution.

Authors:  Manaka Tagaya; Daiji Yoshikawa; Yoshinori Sugishita; Fumi Yamauchi; Takehiro Ito; Tomohito Kamada; Masataka Yoshinaga; Daisuke Mukaide; Wakaya Fujiwara; Hiroatsu Yokoi; Mutsuharu Hayashi; Eiichi Watanabe; Junichi Ishii; Yukio Ozaki; Hideo Izawa
Journal:  Heart Vessels       Date:  2015-05-29       Impact factor: 2.037

3.  The CHADS2 score predicts ischemic stroke in chronic heart failure patients without atrial fibrillation: comparison to other stroke risk scores.

Authors:  Takumi Kondo; Takahisa Yamada; Takashi Morita; Yoshio Furukawa; Shunsuke Tamaki; Yusuke Iwasaki; Masato Kawasaki; Atsushi Kikuchi; Tsutomu Kawai; Satoshi Takahashi; Masashi Ishimi; Hideyuki Hakui; Tatsuhisa Ozaki; Yoshihiro Sato; Masahiro Seo; Yasushi Sakata; Masatake Fukunami
Journal:  Heart Vessels       Date:  2016-06-21       Impact factor: 2.037

4.  Influence of the concomitant use of heparin on the effects of warfarin during catheter ablation for atrial fibrillation.

Authors:  Keiichi Inada; Seiichiro Matsuo; Ken-Ichi Tokutake; Ken-Ichi Yokoyama; Mika Hioki; Ryohsuke Narui; Keiichi Ito; Shin-Ichi Tanigawa; Seigo Yamashita; Michifumi Tokuda; Kenri Shibayama; Satoru Miyanaga; Ken-Ichi Sugimoto; Michihiro Yoshimura; Teiichi Yamane
Journal:  Heart Vessels       Date:  2014-12-04       Impact factor: 2.037

5.  Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation.

Authors:  Sayaka Namba; Minako Yamaoka-Tojo; Ryota Kakizaki; Teruyoshi Nemoto; Kazuhiro Fujiyoshi; Takehiro Hashikata; Lisa Kitasato; Takuya Hashimoto; Ryo Kameda; Kentaro Meguro; Takao Shimohama; Taiki Tojo; Junya Ako
Journal:  Heart Vessels       Date:  2017-02-23       Impact factor: 2.037

6.  Management and outcomes of patients with left atrial appendage thrombus prior to percutaneous closure.

Authors:  Luis Marroquin; Gabriela Tirado-Conte; Radosław Pracoń; Witold Streb; Hipolito Gutierrez; Giacomo Boccuzzi; Dabit Arzamendi-Aizpurua; Ignacio Cruz-González; Juan Miguel Ruiz-Nodar; Jung-Sun Kim; Xavier Freixa; Jose Ramon Lopez-Minguez; Ole De Backer; Rafael Ruiz-Salmeron; Antonio Dominguez; Angela McInerney; Vicente Peral; Rodrigo Estevez-Loureiro; Eduard Fernandez-Nofrerias; Afonso B Freitas-Ferraz; Francesco Saia; Zenon Huczek; Livia Gheorghe; Pablo Salinas; Marcin Demkow; Jose R Delgado-Arana; Estefania Fernandez Peregrina; Zbibniew Kalarus; Ana Elvira Laffond; Yangsoo Jang; Jose Carlos Fernandez Camacho; Oh-Hyun Lee; Jose M Hernández-Garcia; Caterina Mas-Llado; Berenice Caneiro Queija; Ignacio J Amat-Santos; Maciej Dabrowski; Josep Rodés-Cabau; Luis Nombela Franco
Journal:  Heart       Date:  2022-06-24       Impact factor: 7.365

7.  Clinical Characteristics and Prognosis of End-stage Hypertrophic Cardiomyopathy.

Authors:  Yan Xiao; Kun-Qi Yang; Yan-Kun Yang; Ya-Xin Liu; Tao Tian; Lei Song; Xiong-Jing Jiang; Xian-Liang Zhou
Journal:  Chin Med J (Engl)       Date:  2015-06-05       Impact factor: 2.628

8.  Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.

Authors:  Paolo Verdecchia; Gianpaolo Reboldi; Fabio Angeli; Giovanni Mazzotta; Gregory Y H Lip; Martina Brueckmann; Eva Kleine; Lars Wallentin; Michael D Ezekowitz; Salim Yusuf; Stuart J Connolly; Giuseppe Di Pasquale
Journal:  Europace       Date:  2018-02-01       Impact factor: 5.214

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.